echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 22 listed pharmaceutical companies released 2016 "report card", with the highest "profit" of 2.6 billion!

    22 listed pharmaceutical companies released 2016 "report card", with the highest "profit" of 2.6 billion!

    • Last Update: 2017-03-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: Bio exploration 2017-03-22 according to incomplete statistics, from March 6 to 21, another 22 listed companies belonging to the pharmaceutical manufacturing or medical industry sector published their 2016 annual report results Compared with the 14 companies in the first wave (for details, 14 listed pharmaceutical companies issued 2016 "report card" with the highest revenue of 14.127 billion), the number of companies with a revenue of more than 5 billion in the second wave increased significantly, totaling 8; among them, the revenue of East China Pharmaceutical and Baiyunshan exceeded 20 billion yuan In addition, in the second wave of enterprises, six companies had a net profit of more than 1 billion yuan last year, among which Hengrui pharmaceutical ranked first among these enterprises with 2.589 billion yuan Shutai God: on March 21, 2016, Shutai God announced its annual report for 2016 Last year, the company's operating revenue was 1.403 billion yuan, up 12.46% year on year; the net profit attributable to shareholders of listed companies was 257 million yuan, up 21.89% year on year; the basic earnings per share was 0.54 yuan, up 20.00% year on year Xinlitai: with revenue of 3.833 billion, on March 21, xinlitai released its 2016 annual report Last year, the company's operating revenue was 3.833 billion yuan, up 10.23% year on year; the net profit attributable to shareholders of listed companies was 1.396 billion yuan, up 10.31% year on year; the basic earnings per share was 1.33 yuan, up 9.92% year on year Health in the United States: revenue 3.082 billion March 21, health in the United States announced the 2016 annual report The company's operating revenue last year was 3.082 billion yuan, up 46.65% year on year; the net profit attributable to shareholders of listed companies was 339 million yuan, up 30.21% year on year; the basic earnings per share was 0.14 yuan, up 7.69% year on year Guangyuyuan: with revenue of 937 million, on March 21, guangyuyuan announced its 2016 annual report Last year, the company's operating revenue was 937 million yuan, up 118.70% year on year; the net profit attributable to shareholders of the listed company was 123 million yuan, up 5948.84% year on year; the basic earnings per share was 0.44 yuan, up 4300% year on year Guangshengtang: with revenue of 313 million, on March 21, guangshengtang released its annual report for 2016 The company's operating revenue last year was 313 million yuan, an increase of 1.28% year on year; the net profit attributable to shareholders of the listed company was 66.413 million yuan, a decrease of 35.83% year on year; the basic earnings per share was 0.47 yuan, a decrease of 49.35% year on year Liuzhou Pharmaceutical Co., Ltd.: on March 21, 2016, its revenue was 7.559 billion, and its annual report for 2016 was released Last year, the company's operating revenue was 7.559 billion yuan, up 16.16% year on year; the net profit attributable to shareholders of listed companies was 321 million yuan, up 54.05% year on year; the basic earnings per share was 2.34 yuan, up 26.49% year on year Taihe health: on March 21, 2016, Taihe health released its annual report The company's operating revenue last year was RMB 575 million, an increase of 24.15% year on year; the net profit attributable to the shareholders of the listed company was RMB 82497400, an increase of 320.53% year on year; the basic earnings per share was RMB 0.19, an increase of 320.51% year on year Huabei pharmaceutical: on March 18, 2016, Huabei pharmaceutical announced its annual report for 2016 Last year, the company's operating revenue was 8.082 billion yuan, up 2.28% year on year; the net profit attributable to shareholders of listed companies was 54.4151 million yuan, down 13.42% year on year; the basic earnings per share was 0.033 yuan, down 15.38% year on year Fosci pharmaceutical: on March 17, 2016, fosci pharmaceutical announced its annual report The company's operating revenue last year was 363 million yuan, up 10.89% year on year; the net profit attributable to shareholders of listed companies was 60.9262 million yuan, up 41.86% year on year; the basic earnings per share was 0.12 yuan, up 31.24% year on year Lianhuan Pharmaceutical Co., Ltd.: on March 17, 2016, with revenue of 605 million, Lianhuan Pharmaceutical Co., Ltd released its annual report for 2016 Last year, the company's operating revenue was RMB 605 million, down 5.85% year on year; the net profit attributable to shareholders of the listed company was RMB 62.6902 million, up 25.09% year on year; the basic earnings per share was RMB 0.29, up 26.09% year on year Guizhou bailing: on March 16, 2016, the annual report of Guizhou bailing was released The operating income of the company last year was 2 billion 214 million yuan, with a year-on-year growth of 16.59%; the net profit attributable to the shareholders of the listed company was 482 million yuan, with a year-on-year growth of 17.25%; the basic earnings per share was 0.34 yuan, with a year-on-year growth of 17.24% Baiyunshan: on March 16, 2016, Baiyunshan announced its annual report for 2016 The company's operating revenue last year was 20.036 billion yuan, up 4.76% year on year; the net profit attributable to shareholders of listed companies was 1.508 billion yuan, up 15.97% year on year; the basic earnings per share was 1.08 yuan, up 6.76% year on year Dongcheng Pharmaceutical Co., Ltd.: with a revenue of 1.158 billion, on March 16, Dongcheng Pharmaceutical Co., Ltd released its 2016 annual report Last year, the company's operating revenue was RMB 1.158 billion, up 45.73% year on year; the net profit attributable to shareholders of listed companies was RMB 131 million, up 45.92% year on year; the basic earnings per share was RMB 0.20, up 37.24% year on year Pulo pharmaceutical: revenue of 4.772 billion on March 15, pulo pharmaceutical released its 2016 annual report Last year, the company's operating revenue was 4.772 billion yuan, up 10.01% year on year; the net profit attributable to shareholders of the listed company was 263 million yuan, up 26.25% year on year; the basic earnings per share was 0.23 yuan, up 27.78% year on year Xinhua Pharmaceutical: with a revenue of 4.015 billion, on March 15, Xinhua Pharmaceutical released its annual report for 2016 Last year, the company's operating revenue was 4.015 billion yuan, up 11.62% year on year; the net profit attributable to shareholders of listed companies was 122 million yuan, up 47.20%%; the basic earnings per share was 0.27 yuan, up 50.00% year on year Zhifei biology: on March 14, 2014, Zhifei biology released its 2016 annual report Last year, the company's operating revenue was 446 million yuan, a year-on-year decrease of 37.43%; the net profit attributable to shareholders of the listed company was 32.5203 million yuan, a year-on-year decrease of 83.53%; the basic earnings per share was 0.02 yuan, a year-on-year decrease of 83.33% Dong'a Ejiao: its revenue was 6.317 billion on March 13, and it updated its 2016 annual report Last year, the company's operating revenue was 6.317 billion yuan, up 15.92% year on year; the net profit attributable to shareholders of listed companies was 1.852 billion yuan, up 14.00% year on year; the basic earnings per share was 2.83 yuan, up 13.99% year on year Hengrui pharmaceutical: on March 11, 2016, its revenue was 11.094 billion Hengrui pharmaceutical released its annual report for 2016 Last year, the company's operating revenue was 11.094 billion yuan, a year-on-year increase of 19.08%; the net profit attributable to shareholders of the listed company was 2.589 billion yuan, a year-on-year increase of 19.22%; the basic earnings per share was 1.10 yuan, a year-on-year increase of 19.42% China Resources double crane: on March 10, 2016, its revenue was 5.495 billion Last year, the company's operating revenue was 5.495 billion yuan, up 6.94% year on year; the net profit attributable to shareholders of listed companies was 714 million yuan, up 8.04% year on year; the basic earnings per share was 0.99 yuan, up 8.03% year on year East China Pharmaceutical: on March 9, 2016, East China Pharmaceutical announced its annual report with a revenue of 25.38 billion Last year, the company's operating revenue was 25.380 billion yuan, an increase of 16.81% year on year; the net profit attributable to shareholders of listed companies was 1.447 billion yuan, an increase of 31.88% year on year; the basic earnings per share was 3.00 yuan, an increase of 18.58% year on year China Resources 39: revenue of 8.982 billion on March 9, China Resources 39 announced the 2016 annual report Last year, the company's operating revenue was 8.982 billion yuan, up 13.69% year on year; the net profit attributable to shareholders of listed companies was 1.198 billion yuan, down 4.11% year on year; the basic earnings per share was 1.22 yuan, down 4.69% year on year Wanfu biology: on March 8, 2016, Wanfu biology released its annual report The company's operating revenue last year was 547 million yuan, up 27.65% year on year; the net profit attributable to shareholders of listed companies was 145 million yuan, up 15.66% year on year; the basic earnings per share was 0.82 yuan, up 1.23% year on year.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.